RNAZ TransCode Therapeutics Inc
5,712
$1.79
$0.40
(28.78%)
| Watchers | 5,712 |
| 52-Wk Low | $0.42 |
| 52-Wk High | $223.60 |
| Market Cap | $11.76M |
| Volume | 2.25M |
| 52-Wk High | $223.60 |
| 52-Wk Low | $0.42 |
Why TransCode Therapeutics (RNAZ) Stock Is Getting HammeredBenzinga • 14 days ago
TransCode Therapeutics shares are trading lower by 40.6% during Monday's session. The company disclosed plans for a potential reverse stock split in an open letter to its shareholders.
read more...
Share to Feed
Medical oncologist brings over 25 years of industry experience to lead Clinical Development StrategyBOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA...
BOSTON, March 11, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, reported...
Highlights TTX-MC138's Path from Target Discovery to the ClinicBOSTON, March 06, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more...
BOSTON, Feb. 20, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, reported...
BOSTON, Jan. 31, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (the Company ), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics...
Project to test combination of TransCode's proprietary TTX delivery platform and Debiopharm's drug delivery technologiesBOSTON, Jan. 29, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc...
BOSTON, Jan. 22, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the Company ), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics...
BOSTON, Jan. 18, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (the Company ), an RNA oncology company committed to more effectively treating cancer using RNA therapeutics...